OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. started from a private conversation
  2. 1 It is pregabalin + a private exchange
  3. 2 I think I need to take monjaro + a private exchange
  4. 3 Is 7.5 monjaro work
  5. 4 How long will it take to loose a stone on monjaro

Answered on this page ↓

How long will it take to loose a stone on monjaro

Sep 12, 2026 · 3 sources used · OpenNeedle synthesis
The short version: the evidence does not give a precise timeline for losing one stone on Mounjaro, but the trial data lets you estimate it.

The SURPASS trials show that people on 10 mg of tirzepatide lost about 10.3 kg over 40 weeks, and people on 15 mg lost about 12.4 kg [1]. One stone is 6.35 kg. At the 10 mg dose, that would take roughly 24 to 28 weeks, based on the rate of loss in those trials. At 15 mg, it would be closer to 20 to 24 weeks. A 2025 network meta-analysis found tirzepatide produced an average 11.82 kg weight loss versus placebo [2], which matches the same range.

But these are averages from clinical trials where people also received diet and exercise counseling. Real-world results vary. The SURMOUNT trials in non-diabetic people showed 15 mg produced about 20.9% weight loss at 72 weeks [3], which for a 100 kg person would be about 21 kg. That rate works out to roughly 0.3 kg per week, meaning one stone would take about 21 weeks.

The dose matters. The 7.5 mg dose you asked about in your previous question sits between the 5 mg and 10 mg studied doses. The 5 mg dose produced about 7.8 kg loss over 40 weeks [1], which is a slower rate. At 7.5 mg, you would likely land between the two, so one stone might take 28 to 32 weeks.

Weight loss is not linear. People lose faster in the first few weeks and slower later. Gastrointestinal side effects like nausea and diarrhea are common [3] and can slow progress if they cause you to stop the drug. About 4 to 7 in 100 people stopped tirzepatide due to side effects in the trials [3].

My call: expect one stone in 20 to 28 weeks at 10 mg or 15 mg, and 28 to 32 weeks at 7.5 mg. Confidence: moderate. The trial data is solid for average rates, but individual results vary widely and the evidence does not include a head-to-head timeline study.

Keep digging

Sources used 3

  1. Multiagonists of the “incretin axis” as a promising tool for managing cardiometabolic risk in visceral obesity Russian Journal of Cardiology (2021) Thin

    Unimolecular dual and triple incretin-axis agonists that co-activate GLP-1, GIP, and glucagon receptors show promise for reducing cardiometabolic risk in visceral obesity, with multiple phase 2–3 trials reporting substantial weight loss and glycemic improvements compared with GL…

    DOI: 10.15829/1560-4071-2022-4755
  2. SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials Journal of the Endocrine Society (2025) Thin

    This network meta-analysis compares tirzepatide and retatrutide for weight loss across randomized trials, finding retatrutide yields greater weight loss but with more adverse events than tirzepatide and highlighting the need for direct head-to-head trials.

    DOI: 10.1210/jendso/bvaf149.169
  3. Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review Obesities (2025) Thin

    A narrative review synthesizing current clinical evidence on the efficacy and safety of tirzepatide for weight management in non-diabetic obese adults, showing substantial weight loss and cardiometabolic benefits across multiple SURMOUNT trials with generally GI-dominant adverse…

    DOI: 10.3390/obesities5020026

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question